OUR MISSION
Alzheimer’s disease is a devastating neurodegenerative disorder that is characterized progressive loss of brain functions such as memory and ultimately leads to death of the patient. Alzheimer’s disease currently affects more than 40 million people, which is expected to rise to 115 million in 2050. It will therefore be one of the biggest health care epidemics of the 21st century.
The prolonged disease demands a significantly high degree of personal attention from the healthcare workforce. Developed economies are increasingly burdened by its heavy costs. With aging populations and no available treatments that halt the disease progression, finding solutions has never been more urgent.
Maptimmune develops next-generation therapies for the treatment of Alzheimer’s disease, with the aim of reducing the global burden of dementia.